

21 Science Park Road, #03-03 The Aquarius, Singapore 117628
Phone: 65-6777-8775 Fax: 65-6777-3079

**Scitech Medical
Products Pte. Ltd.**

Fax

To: Julia/Hugh Dowling - Bell Potter	From: David M. Mashaal - SCITECH MEDICAL
Fax: +61 (2) 92557481	Pages: 7 (including cover)
Phone:	Date: 3/14/2006
Re: Scitech Genetics	CC:

Urgent **For Review** **Please Comment** **Please Reply** **Please Recycle**

Dear Julia/Hugh,

Please disregard the last fax and send this one in place of it. I neglected to add the details and was instructed that it is better to do so.

Please find attached our Form 605 with Annex A and two different Form 3Y.

Please forward these off to ASX for me.

Thank you,



David Mashaal
Director

Appendix 3Y
Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	SciGen Ltd
ARBN	101 318 852

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Saul Mashaal
Date of last notice	20.02.06

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director and Shareholder (Scitech Genetics Pte Ltd)
Date of change	09.03.06
No. of securities held prior to change	100,692,832
Class	CUFS
Number acquired	-
Number disposed	100,692,832

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	(1) Scitech agreed to sell its SciGen Shares to Bioton for A\$0.075 per SciGen Share whereby Scitech will obtain a cash payment from Bioton of an aggregate of A\$7,551,962.40; (2) Scitech agreed to subscribe for an aggregate of 2,020,579 new ordinary shares of 1.0 Polish Zloty each in the capital of Bioton (the "Bioton Consideration Shares") at a subscription price of 7.4 Polish Zloty per Bioton Consideration Share. This works out to be approximately A\$5,973,268.06; and (3) Scitech agreed to undertake that it shall not sell (i) 50% of the Bioton Consideration Shares for a period of 6 months and (ii) the remaining 50% of the Bioton Consideration Shares for the period of 18 months from the date such Bioton Consideration Shares are acquired. (4) After setting-off part of the cash payment in Paragraph (1) against the subscription monies in Paragraph (2) above, the net cash amount payable by Bioton to Scitech would be approximately A\$1,578,694.34.
No. of securities held after change	0
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Off-market Trade
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	SciGen Ltd
ARBN	101 318 852

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Kenneth Gross
Date of last notice	20.02.06

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director and Shareholder (Scitech Genetics Pte Ltd)
Date of change	09.03.06
No. of securities held prior to change	100,692,832
Class	CUFS
Number acquired	-
Number disposed	100,692,832

+ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>(1) Scitech agreed to sell its SciGen Shares to Bioton for A\$0.075 per SciGen Share whereby Scitech will obtain a cash payment from Bioton of an aggregate of A\$7,551,962.40; (2) Scitech agreed to subscribe for an aggregate of 2,020,579 new ordinary shares of 1.0 Polish Zloty each in the capital of Bioton (the "Bioton Consideration Shares") at a subscription price of 7.4 Polish Zloty per Bioton Consideration Share. This works out to be approximately A\$5,973,268.06; and (3) Scitech agreed to undertake that it shall not sell (i) 50% of the Bioton Consideration Shares for a period of 6 months and (ii) the remaining 50% of the Bioton Consideration Shares for the period of 18 months from the date such Bioton Consideration Shares are acquired. (4) After setting-off part of the cash payment in Paragraph (1) against the subscription monies in Paragraph (2) above, the net cash amount payable by Bioton to Scitech would be approximately A\$1,578,694.34.</p>
<p>No. of securities held after change</p>	<p>0</p>
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	<p>Off-market Trade</p>
<p>Nature of interest</p>	
<p>Name of registered holder (if issued securities)</p>	
<p>Date of change</p>	
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	
<p>Interest acquired</p>	
<p>Interest disposed</p>	
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	
<p>Interest after change</p>	

+ See chapter 19 for defined terms.